BUSINESS● LOW2h ago · Oct 4, 2026, 10:41 PM
CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug
Seeking Alpha Tech · global
CSL has entered into a $1.6 billion agreement with Alentis for an experimental kidney and liver drug. This represents a major pharmaceutical business deal focused on new medical treatments.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS33m agoBlackstone lands a 'supercontract' for state housing management while the Government places it among "vulture funds"El MundoBUSINESS1h agoManchester City must be relegated, says Canada’s ex-Leeds managerAl Jazeera [en]